MediWound Presents at J.P. Morgan Healthcare Conference

Ticker: MDWD · Form: 6-K · Filed: Jan 8, 2024 · CIK: 1593984

Mediwound Ltd. 6-K Filing Summary
FieldDetail
CompanyMediwound Ltd. (MDWD)
Form Type6-K
Filed DateJan 8, 2024
Risk Levellow
Pages1
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: investor-presentation, corporate-update

TL;DR

**MediWound just presented at J.P. Morgan, sharing future financial estimates and product updates.**

AI Summary

MediWound Ltd. presented at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, showcasing its commercial and clinical products, along with future financial estimates. This matters to investors because the presentation materials, available on MediWound's website and as Exhibit 99.1, offer insights into the company's strategic direction and potential future performance, which could influence stock valuation.

Why It Matters

This filing indicates MediWound is actively engaging with the investment community, providing transparency and potentially attracting new investors or reassuring existing ones about its future prospects.

Risk Assessment

Risk Level: low — This 6-K filing is a routine disclosure of a presentation at an investor conference and does not introduce new material risks.

Analyst Insight

A smart investor would review the presentation materials (Exhibit 99.1) on MediWound's website to understand the company's product pipeline and financial outlook, as these details could impact future stock performance.

Key Players & Entities

  • MediWound Ltd. (company) — the registrant making the filing
  • J.P. Morgan (company) — host of the 42nd Annual Healthcare Conference
  • January 8, 2024 (date) — date of the presentation and filing

FAQ

What was the purpose of MediWound Ltd.'s 6-K filing on January 8, 2024?

The purpose of MediWound Ltd.'s 6-K filing on January 8, 2024, was to report that the company made a presentation at the J.P. Morgan 42nd Annual Healthcare Conference, and to furnish the presentation materials as Exhibit 99.1.

What information did MediWound Ltd. highlight in its presentation at the J.P. Morgan conference?

In its presentation at the J.P. Morgan 42nd Annual Healthcare Conference, MediWound Ltd. highlighted its commercial product, its clinical products, and certain estimates and projections regarding expected future financial results and information.

Where can investors find the materials used in conjunction with MediWound's presentation?

The materials used in conjunction with MediWound Ltd.'s presentation are available on the Company's website at www.mediwound.com and are furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

What is MediWound Ltd.'s stance on updating the forward-looking statements made in the presentation?

MediWound Ltd. states that the information in the presentation is provided as of January 8, 2024, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

What is the significance of the furnishing of the presentation materials in this 6-K?

The furnishing of the materials related to the presentation is not an admission as to the materiality of any information contained in those materials, according to the filing.

Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-01-08 07:00:25

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __ CONTENTS On January 8, 2024, MediWound Ltd. (the "Company") made a presentation at the J.P. Morgan 42 nd Annual Healthcare Conference, highlighting its commercial product, its clinical products as well as certain estimates and projections as to expected future financial results and information. Materials used in conjunction with the presentation are available on the Company's website at www.mediwound.com and are furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K"). The contents of the foregoing website are not a part of this Form 6-K. The information contained in the presentation is provided as of January 8, 2024, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results. The furnishing of the materials related to the presentation is not an admission as to the materiality of any information contained in those materials. The content of this report on Form 6-K (including the information contained in Exhibit 99.1), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 8, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3 EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Corporate Presentation of MediWound Ltd. dated January 2024. 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.